Tesamorelin: Dosage, Protocol, and Research Guide
FDA-approved GHRH analog for reducing visceral adipose tissue, particularly effective for metabolic syndrome
Mechanism
Synthetic GHRH analog that stimulates pituitary somatotrophs to release GH in a physiologic, pulsatile manner. Specifically reduces visceral adipose tissue through lipolysis while preserving subcutaneous fat and lean mass.
Protocol at a glance
| Starting dose | 1mg |
|---|---|
| Maintenance dose | 1-2mg |
| Maximum dose | 2mg |
| Frequency | Once daily |
| Typical duration | Ongoing with regular IGF-1 monitoring |
| Route | Subcutaneous |
| Injection site | Abdomen |
| Timing | At least 90 minutes after last meal, typically before bedtime |
Side effects
- Mild injection site irritation
- Transient water retention
- Nausea or mild GI discomfort
- Arthralgia
Contraindications
- Active cancer
- History of IGF-1 related concerns
- Pregnancy
- Disruption of hypothalamic-pituitary axis
Protocol notes
- FDA approved for HIV-associated lipodystrophy
- Specifically reduces visceral abdominal fat
- Improves lipid profiles and insulin sensitivity
- Elevates IGF-1 levels - regular monitoring recommended
- Aligns with natural GH secretion cycles when taken before bed
- Beneficial for metabolic syndrome and central obesity
Frequently asked questions
What is Tesamorelin and how does it work?
Tesamorelin is a synthetic GHRH (growth hormone-releasing hormone) analog that stimulates the pituitary gland to release growth hormone in a physiologic, pulsatile manner. Rather than providing exogenous hormone, it activates the body's own endocrine axis, preserving natural feedback regulation and circadian secretion patterns. This mechanism makes it physiologically distinct from direct growth hormone replacement.
What is the typical dosing protocol for Tesamorelin?
Tesamorelin dosing begins at 1 mg administered once daily via subcutaneous injection. Maintenance doses typically range from 1–2 mg daily, adjusted based on individual response and IGF-1 levels. The medication is designed for ongoing use with regular monitoring rather than discontinuous cycling, and is most commonly administered in the evening at least 90 minutes after the last meal, ideally before bedtime to align with natural circadian growth hormone secretion.
What are the side effects of Tesamorelin?
Common side effects are mild and transient, including localized injection site irritation, transient water retention, mild nausea or gastrointestinal discomfort, and arthralgia (joint discomfort). The side effect profile is notably favorable compared to pharmacologic growth hormone replacement due to Tesamorelin's mechanism of stimulating endogenous hormone secretion rather than providing supraphysiologic exogenous hormone.
How should Tesamorelin be administered?
Tesamorelin is administered via subcutaneous injection in the abdomen. The timing is critical: inject at least 90 minutes after the last meal, with evening administration before bedtime being preferred to align with the body's natural circadian growth hormone secretion cycle. Subcutaneous administration allows for consistent absorption and enables patient self-injection with proper training.
What lab markers should be monitored during Tesamorelin therapy?
IGF-1 (insulin-like growth factor 1) is the primary marker that should be monitored regularly during Tesamorelin therapy, as it reflects stimulation of the growth hormone axis. Elevated IGF-1 indicates increased growth hormone activity, and monitoring ensures levels remain in a physiologic rather than supraphysiologic range. Additionally, improvements in metabolic markers such as lipid profiles and fasting glucose may be tracked to assess the medication's metabolic benefits.
What are the contraindications for Tesamorelin?
Tesamorelin is contraindicated in individuals with active cancer, history of IGF-1-related concerns, pregnancy, or disruption of the hypothalamic-pituitary axis. Because the medication works by stimulating the pituitary gland, any condition affecting pituitary function or any concern about elevated IGF-1 represents a relative or absolute contraindication. Physician evaluation is essential before initiating therapy.
How long does Tesamorelin therapy typically last?
Tesamorelin is designed for ongoing use with regular monitoring rather than short-term cycles. Unlike some other peptide therapies, there is no defined 'stop date' for Tesamorelin; therapy continues as long as the individual benefits and tolerates the medication well, with regular IGF-1 and metabolic monitoring. The decision to discontinue or modify therapy is made collaboratively with a physician based on clinical response and goals.
Is Tesamorelin legal, and what is its approval status?
Tesamorelin is FDA-approved specifically for the management of HIV-associated lipodystrophy. It is a prescription medication available through licensed healthcare providers. The legal and approval status of Tesamorelin varies by jurisdiction and intended use. Always consult with a licensed physician regarding the legality and appropriateness of any therapeutic intervention in your region.
More Growth Hormone Peptides peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.